Loading...
EGFR targeting of Lu-177 gold nanoparticles to colorectal and breast tumour cells: Affinity, duration of binding and growth inhibition of Cetuximab-resistant cells
Shabbir, Rekaya Mingarelli, M. Cabello, G. van Herk, Marcel Choudhury, Ananya Smith, Tim A D
Shabbir, Rekaya
Mingarelli, M.
Cabello, G.
van Herk, Marcel
Choudhury, Ananya
Smith, Tim A D
Citations
Altmetric:
Abstract
Objective:Radioimmunotherapy (RIT) is a systemic therapy currently used in the treatment of patientswith lymphoma. RIT complexes consist of a targeting molecule, commonly an antibody, radionuclide che-lates and a linker which can be a nanoparticle platform. Nanoparticles facilitate the attachment of mul-tiple radionuclides and targeting groups to a single complex. Here the target affinity, duration of targetassociation and inhibition of colony formation of Cetuximab-resistant tumour cells with Cetuximab-targeted [177Lu]-AuNPs were investigated. Dose distribution in xenografts derived from EGFR-overexpressing cells was also determined.Methods:Cetuximab-targeted [177Lu]-AuNPs were generated by functionalising 15nm AuNPs with thechelator DOTA and Cetuximab and radiolabelling with177LuCl3.KDis, a measure of affinity, was deter-mined by competitive binding to EGFR expressing cells. Radio-sensitivity was determined in EGFRexpressing tumour cells including the Cetuximab resistant cell line HCT116 using a colony formationassay. Dose distribution was measured in sections from xenografts grown in nude mice using autoradio-graphy.Results:KDisfor the complex binding to EGFR on MDA-MB-468 cells was 20 nM. Loss of cell associated[177Lu] activity was biphasic with loss of about 50% of activity in about 4 h. Remaining activity dissociatedover a period of about 4 days. HCT8 and MDA-MB-468, but not HCT116 cells were sensitive to the growthinhibitory effect of Cetuximab. However, treatment with Cetuximab-targeted [177Lu]-AuNPs inhibitedcolony formation in all 3 cell lines. Dose distribution across sections from xenografts was found todemonstrate a co-efficient of variation of 15%.Conclusion:Cetuximab-targeted [177Lu]-AuNPs demonstrate high affinity for EGFR and could be an effec-tive treatment for Cetuximab-resistant colorectal cancer cells. A strategy involving pre-treatment withreceptor targeted[177Lu] to improve RIT therapeutic ratios has the potential to enhance clinical outcomes.
Description
Date
2021
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 581.84 KB
Keywords
Type
Article
Citation
Shabbir R, Mingarelli M, Cabello G, van Herk M, Choudhury A, Smith TAD. EGFR targeting of [177Lu] gold nanoparticles to colorectal and breast tumour cells: Affinity, duration of binding and growth inhibition of Cetuximab-resistant cells [Internet]. Vol. 33, Journal of King Saud University - Science. Elsevier BV; 2021. p. 101573.